At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
LEO90100 cutaneous spray, ointment +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
In Brief
A Phase 2 clinical trial evaluating LEO90100 cutaneous spray, ointment, LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate, and 2 other interventions for Psoriasis Vulgaris. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of the study is to evaluate the anti-psoriatic effect of LEO 90100 cutaneous spray ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedMay 2011
Primary CompletionJun 2011
TodayJul 2026
First PostedMay 4, 2011
Enrollment StartMay 1, 2011
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.2 years ago
Interventions
LEO90100 cutaneous spray, ointmentdrug
once daily application, 4 weeks
LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionatedrug
once daily application, 4 weeks
LEO 90100 cutaneous spray, ointment, vehicledrug
once daily application, 4 weeks
Daivobet® ointmentdrug
once daily application, 4 weeks